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Abstract
Background: Natural history models of human papillomavirus (HPV) infection and disease have been
used in a number of policy evaluations of technologies to prevent and screen for HPV disease (e.g., cervical
cancer, anogenital warts), sometimes with wide variation in values for epidemiologic and clinical inputs.
The objectives of this study are to: (1) Provide an updated critical and systematic review of the evidence
base to support epidemiologic and clinical modeling of key HPV disease-related parameters in the context
of an HPV multi-type disease transmission model which we have applied within a U.S. population context;
(2) Identify areas where additional studies are particularly needed.
Methods: Consistent with our and other prior HPV natural history models, the literature review was
confined to cervical disease and genital warts. Between October 2005 and January 2006, data were
gathered from the published English language medical literature through a search of the PubMed database
and references were examined from prior HPV natural history models and review papers. Study design
and data quality from individual studies were compared and analyses meeting pre-defined criteria were
selected.
Results:  Published data meeting review eligibility criteria were most plentiful for natural history
parameters relating to the progression and regression of cervical intraepithelial neoplasia (CIN) without
HPV typing, and data concerning the natural history of HPV disease due to specific HPV types were often
lacking. Epidemiologic evidence to support age-dependency in the risk of progression and regression of
HPV disease was found to be weak, and an alternative hypothesis concerning the time-dependence of
transition rates is explored. No data were found on the duration of immunity following HPV infection. In
the area of clinical management, data were observed to be lacking on the proportion of clinically manifest
anogenital warts that are treated and the proportion of cervical cancer cases that become symptomatic
by stage.
Conclusion: Knowledge of the natural history of HPV disease has been considerably enhanced over the
past two decades, through the publication of an increasing number of relevant studies. However,
considerable opportunity remains for advancing our understanding of HPV natural history and the quality
of associated models, particularly with respect to examining HPV age- and type-specific outcomes, and
acquired immunity following infection.
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Background
It is estimated that genital human papillomavirus (HPV)
infection is responsible for approximately 500,000 cervi-
cal cancer cases and 275,000 associated deaths worldwide
each year [1,2]. HPV has also been linked in varying
degrees to cancers of the anus, vulva, vagina, penis, and
head and neck, as well as anogenital warts and recurrent
respiratory papillomatoses (RRP) [3-6].
In recent years, a number of natural history models of
HPV disease have been developed and used in policy eval-
uations of the cost-effectiveness of emergent technologies
to prevent and screen for HPV-related disease, such as
HPV vaccination [7-10], liquid-based cervical cytology
[11] and HPV testing [12,13]. Although the purpose and
structure of each model have differed somewhat, a com-
mon thread across analyses has been the baseline mode-
ling of progression and regression of HPV infection
through potential outcomes of cervical cancer and death,
and the overlaying of clinical diagnostic and treatment
variables (e.g., potential detection of abnormal cervical
cells through Pap screening) for HPV disease. Nonethe-
less, even where a particular parameter has been common
to several natural history models, the chosen values have
at times varied widely. For instance, for estimating the
annual proportion of untreated cervical intraepithelial
neoplasia (CIN) grade 1 lesions regressing, two economic
evaluations of HPV vaccination published by Sanders et
al. in 2003 [9] and Goldie et al. in 2004 [7] assumed very
different parameter values and ranges (2.7–14.2% vs. ≥
79.7%).
The degree to which variation in a parameter value will
influence model output and results will depend upon the
particular parameter, model, intervention and output in
question. Based on the observed variation in parameter
estimates in existing HPV natural history models, we
elected to conduct a critical and systematic review of the
literature on the epidemiologic natural history and clini-
cal outcomes of HPV disease, in developing an HPV
multi-type disease transmission model which we have
applied within a U.S. population context [14] Our find-
ings are presented here, with the goals of: (1) Providing a
review and discussion of the evidence base to support epi-
demiologic and clinical modeling of key HPV disease-
related parameters for policy evaluations; (2) Identifying
areas where research data are lacking and additional stud-
ies are particularly needed.
Methods
Scope of review
Overviews of the epidemiologic and clinical structure of
our HPV multi-type model are presented in Figures 1 and
2. In the model, incident HPV 6, 11, 16 and 18 infections
arise through sexual mixing of males and females in the
population. The sexual mixing matrix, along with a
description of other model components (e.g., population
demographic characteristics, economic costs of care,
health-related quality of life) are described elsewhere [14].
The present systematic review focuses upon natural his-
tory model health state transitions ranging from HPV
infection through HPV disease and associated mortality.
Unlike sexual mixing, these parameters are generally com-
mon to most prior cohort-based and dynamic transmis-
sion models of HPV disease [10-13].
Consistent with the model, our review is also confined to
the epidemiologic natural history and clinical outcomes
of cervical HPV disease and genital warts. Prior HPV natu-
ral history models to ours had generally examined only a
single facet of HPV disease [7-9,15] and the incorporation
of both cervical disease and genital warts into a single
model represented a step forward. However, further
research is on-going to evaluate and incorporate the natu-
ral history of other HPV-related diseases (e.g., other geni-
tal cancers, head and neck cancer and RRP). Also, in the
model and our present review, we focus specifically upon
the natural histories of HPV 6, 11, 16 and 18 infections as
HPV types 16 and 18 are responsible for approximately
70% of cervical cancers [16] and types 6 and 11 the vast
majority of genital warts[17,18] and reflect the types tar-
geted by one or both of the prophylactic HPV vaccines
[19,20], which were the subject of our model technology
assessment [14]. Few data are currently published on dis-
ease natural history relating to other HPV types, but we
may expand our model to include additional HPV types as
such information becomes available.
Certain clinical parameters (i.e., rates of Pap screening/
coverage, rates of hysterectomy, cervical cancer mortality
by stage) would be expected to vary by country. For
instance, Pap testing coverage and hysterectomy rates may
vary according to local guidelines, resources and cultural
factors and cervical cancer mortality rates by stage in rela-
tion to the availability of specific treatments. In this
review, parameters most likely to vary by country are
described for the U.S. population, however data source
selection issues may also be applicable to other settings.
Where applicable, for further illustration, we additionally
reference data sources used in adaptations of our model to
selected other country settings. Finally, although often
sharing many parameters in common, it is recognized that
heterogeneity exists in the structure of different HPV nat-
ural history models. For instance, some models lump CIN
2 and CIN 3 into a single health state (CIN 2/3)
[13,21,22], while others model them as separate states
[14,23,24]. A discussion of data to inform parameters for
all possible permutations in model structure is beyond
the scope of this review, however, data sources and meth-
odologic issues discussed for the particular model struc-BMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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ture illustrated in the present study (Figures 1 and 2) will
in large part have applicability to other models as well.
Literature Review Design
For development of our model, between October 2005
and January 2006, data were gathered from the published
English language medical literature through searches of
the PubMed database as well as from published reports
and statistics available on the internet and CD-ROM. Ref-
erences were also examined from prior HPV natural his-
tory models [8,9,11,13,21-26] and review papers [27-30].
Because the parameters encompassed within the model
were diverse, ranging from HPV infection to cervical can-
cer to hysterectomy, separate literature searches within
PubMed were conducted for ten different parameter
groups: (1) Duration and progression of cervical HPV
infection and natural immunity; (2) Progression and
regression of cervical intraepithelial neoplasia; (3) Natu-
ral history of cervical cancer; (4) Hysterectomy; (5) Cervi-
cal cytology screening; (6) Cervical cytology sensitivity
and specificity; (7) Symptom development for cervical
cancer; (8) Eradication of HPV disease with treatment; (9)
HPV persistence following treatment; (10) Anogenital
wart patients seeking physican care. The specific constella-
tions of search terms utilized for each of these parameter
groups, along with a listing of the number of articles
retrieved from PubMed and selected for this review, are
reported in detail in Table 1.
General Methodologic Criteria
A number of prior analyses have discussed methodologi-
cal challenges in describing the natural history of HPV dis-
Overview of epidemiologic structure of multi-HPV type model Figure 1
Overview of epidemiologic structure of multi-HPV type model. HPV infection may progress to either genital warts or 
cervical disease, with regression possible for HPV infection, CIN grades 1–3 and genital warts. Only cervical cancer confers an 
added risk of mortality, as depicted in the figure. However, in the full model (not shown for simplicity) all individuals face an 
underlying age and sex-specific mortality rate due to non-cervical cancer-related causes. CIN = Cervical Intraepithelial Neopla-
sia; HPV = Human Papillomavirus.
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ease [27,29-31], and several explicit choices concerning
alternate data sources and study designs were made in the
present review. Given the diversity of model parameters
examined, data sources and selection criteria unique to
specific model parameters will be discussed within their
respective sections in the Results, with an overall sum-
mary provided in Table 2. This section describes general
literature review methodologic criteria applicable to mul-
tiple parameters.
Cytology vs. Histology
The multi-HPV type mode; [14] (henceforth, the model),
like others previously developed, is structured to allow for
progression and regression between cervical histological,
rather than cytological, health states. Therefore, in assess-
ing the natural history of cervical intraepithelial neoplasia
(CIN) and cancer, only studies with histologically con-
firmed disease were eligible for inclusion as data sources.
While less invasive, studies that use cervical cytologic
diagnoses (e.g., atypical squamous cells of undetermined
significance [ASCUS], atypical glandular cells [AGC], low-
grade squamous intraepithelial lesion [LSIL], high-grade
SIL [HSIL]), rather than histology (CIN 1–3), are viewed
as less reliable proxies for the presence and grade of
underlying CIN. For instance, in the ASCUS/LSIL Triage
Study (ALTS), biopsying only women with cytologic diag-
Overview of clinical structure of multi-HPV typemodel Figure 2
Overview of clinical structure of multi-HPV typemodel. HPV infection may progress to either genital warts or cervical 
disease, with regression possible for HPV infection, CIN grades 1–3 and genital warts. Treated genital warts, CIN and cervical 
cancer may result in disease eradication with elimination of HPV infection, disease eradication with persistent HPV infection, or 
failure to eradicate disease or HPV infection. Once CIN is detected, women are followed with annual Pap screening. Women 
in all health states are also subject to an age-specific rate of hysterectomy for benign conditions (not shown for simplicity). CIN 
= Cervical Intraepithelial Neoplasia; HPV = Human Papillomavirus.
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Table 1: Description of Literature Search
Category Search terms Articles Retrieved Articles Selected for this Review
Duration and progression of cervical 
HPV infection and natural immunity
<human papillomavirus and cervical> OR 
<human papillomavirus and cervix>
7,454 8
Progression and regression of cervical 
intraepithelial neoplasia
<cervical intraepithelial neoplasia and 
progression> OR <CIN and 
progression> OR <cervical intraepithelial 
neoplasia and natural history> OR <CIN 
and natural history> OR <cervical 
intraepithelial neoplasia and regression> 
OR <CIN and regression> OR <cervical 
intraepithelial neoplasia and clearance> 
OR <CIN and clearance>
1,321 5
Natural history of cervical cancer <cervical and cancer and natural history> 
OR <cervix and cancer and natural 
history> OR <cervical and cancer and 
progression> OR <cervix and cancer and 
progression>
2,538 4
Hysterectomy <hysterectomy and rate and United 
States>
270 1
Cervical cytology screening <Pap and rate and United States> OR 
<cervical and screening and rate and 
United States> OR <cervix and screening 
and rate and United States> OR 
<cervical and cytology and rate and 
United States> OR <cervix and cytology 
and rate and United States>
848 3
Cervical cytology sensitivity and 
specificity
For literature published up to October 
1999 we consulted a prior systematic 
review:
559 2
Nanda K, McCrory DC, Myers ER, 
Bastian LA, Hasselblad V, Hickey JD, 
Matchar DB. Accuracy of the 
Papanicolaou test in screening for and 
follow-up of cervical cytologic 
abnormalities: a systematic review. Ann 
Intern Med. 2000 May 16;132(10):810–9.
For literature published from October 
1999 forward we used search terms of:
<Pap and cervical intraepithelial neoplasia 
and sensitivity> OR <cytology and 
cervical intraepithelial neoplasia and 
sensitivity> OR <screening and cervical 
intraepithelial neoplasia and sensitivity> 
OR <Pap and cervical intraepithelial 
neoplasia and specificity> OR <cytology 
and cervical intraepithelial neoplasia and 
specificity> OR <screening and cervical 
intraepithelial neoplasia and specificity> 
OR <Pap and CIN and sensitivity> OR 
<cytology and CIN and sensitivity> OR 
<screening and CIN and sensitivity> OR 
<Pap and CIN and specificity> OR 
<cytology and CIN and specificity> OR 
<screening and CIN and specificity>
Symptom development for cervical 
cancer
<cervical and cancer and symptom> OR 
<cervix and cancer and symptom>
255 0BMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
Page 6 of 26
(page number not for citation purposes)
noses of = HSIL was observed to lead to ~60% fewer diag-
noses of CIN 2/3 than performing colposcopy and biopsy
on all women, or triaging women to colposcopy based on
a high-risk positive HPV test. Also there was a substan-
tially smaller proportion of women with HSIL Pap smears
(30–35%) than were diagnosed with CIN 2/3 in the other
trial arms [32]. In addition to the potential for missing
more true disease, there is also the potential for either dis-
ease misclassification, or a false positive result on cytol-
ogy. Even for HSIL cytology, in the ALTS trial, 40% of
cases were followed by a histological diagnosis less severe
than CIN 2/3 during follow-up, without further treatment
[32].
It has been hypothesized that biopsies may alter the natu-
ral history of cervical disease [30,31], which has at times
been used to support the use of cytologic versus histologic
natural history study data. A randomized clinical trial
using digital imaging colposcopy of women undergoing
no biopsy, central biopsy and peripheral biopsy at base-
line found no significant difference in change in lesion
size across the three groups at 6 week follow-up [33]. Fur-
thermore, loop electro-surgical excision procedures
(LEEPs) performed at the same visit confirmed that none
of the CIN 1–3 cases detected on punch or peripheral
biopsy were eliminated due to the biopsy procedure.
Recent reviews of the issue have concluded that while the
use of larger wedge biopsies in early studies may have led
to greater concerns regarding alteration of CIN natural
history, there is not evidence to suggest that the small vol-
ume of tissue removed in central biopsies significantly
affects the natural course of disease [31,34].
Classification and Quality of HPV Testing and Typing
The past two decades have seen major advances in the
quality of HPV testing and typing techniques available.
Early studies characterized the presence or absence of HPV
infection using Pap smear cytologic impressions [35], dot
filter hybridization [36], southern blot hybridization [37]
and other techniques. In studies involving the detection of
individual HPV types, polymerase chain reaction (PCR)
techniques are now widely used over these other methods
and have generally been shown to be of higher quality
[38,39]. In describing the type-specific natural histories of
HPV 6, 11, 16 and 18 infections, studies utilizing non-
Eradication of disease with treatment <cervical intraepithelial neoplasia and 
treatment and loop excision and 
recurrence> OR <cervical intraepithelial 
neoplasia and treatment and LEEP and 
recurrence> OR <cervical intraepithelial 
neoplasia and treatment and LLETZ and 
recurrence> OR <cervical intraepithelial 
neoplasia and treatment and loop 
excision and residual> OR <cervical 
intraepithelial neoplasia and treatment 
and LEEP and residual> OR <cervical 
intraepithelial neoplasia and treatment 
and LLETZ and residual> OR <cervical 
intraepithelial neoplasia and treatment 
and loop excision and failure> OR 
<cervical intraepithelial neoplasia and 
treatment and LEEP and failure> OR 
<cervical intraepithelial neoplasia and 
treatment and LLETZ and failure> OR 
<genital wart and treatment and 
recurrence>
362 10
HPV persistence following treatment <human papillomavirus and treatment 
and persistence> OR <human 
papillomavirus and treatment and 
clearance>
162 2
Anogenital wart patients seeking 
physican care
<genital wart and untreated> OR 
<genital wart and undiagnosed> OR 
<genital wart and care seeking>
36 0
Name of host: PubMed http://www.ncbi.nlm.nih.gov/sites/entrez
Dates of search: October 2005–January 2006
Years covered by search: 1950–2006
Language: English language literature
Complete search strategy used: Different search terms were used for various components of HPV infection and disease epidemiology and 
clinical management. These terms are summarized here by category.
Table 1: Description of Literature Search (Continued)BMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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Table 2: Summary of Study Selection Criteria By Parameter Group
Parameter Group Study Selection Criteria
General criteria for stud y selection • Nationally representative studies meeting selection criteria
➢ If unavailable, then select broad population-based studies
▪ If unavailable, then select local studies
• Specificity of results to HPV type groupings of interest (16/18 or 6/11)
➢ If studies specific to HPV 16/18 or 6/11 infection or disease are unavailable, 
then select studies of all high-risk or all low-risk HPV types, respectively
▪ If unavailable then select studies for all infections or disease
• PCR-based methods for HPV detection in infections
Progression of HPV infection and disease • Histologic confirmation of cervical disease
• Data available for outcomes reported over a 12-month time horizon
HPV infection mean duration in absence of detectable disease • Specificity of results to HPV type groupings of interest (16/18 or 6/11)
• Truncation of infection duration at time of disease detection via histology
• Limited degree of censoring beyond longest infection follow-up time
Regression of HPV infection and disease • Histologic confirmation of cervical disease at baseline
• Biopsy confirmation of cervical HPV-type specific disease absence during follow-
up to connote regression
➢ If unavailable for all cases, then select studies with either biopsy confirmed 
HPV-type specific disease absence for a portion of cases, with negative cytology 
for non-biopsied cases, OR biopsy confirmed disease absence, irrespective of 
HPV-type
• Data available for outcomes reported over a 12-month time horizon
Cervical cancer mortality • Data available on an age- and stage-specific basis
• Nationally representative or broad population-based studies in unscreened 
women
➢ If unavailable, then select nationally representative or broad population-based 
studies in screened and unscreened women
• Data available for outcomes reported over a 12-month time horizon
Hysterectomy for non-HPV related conditions • Age-specific annual hysterectomy rates reported
Cytology screening rates • Age-specific annual routine cervical cytology screening rates reported
➢ Routine screening reported separately from follow-up screening
➢ Cervical cytology reported separately from vaginal cytology
• Data based on documented screening utilization in a population-based study if 
available
➢ If unavailable, then select studies based on patient self-report
Cytology sensitivity • Liquid-based cytology evaluated
• Cervical biopsy performed on all women
➢ If unavailable, then select studies in which cervical biopsy was performed on 
at least a random sample of women with negative cytology and colposcopy 
results
Cytology specificity • Liquid-based cytology evaluated
• Cervical colposcopy performed on all women, with biopsy performed if 
abnormalities suspected
• Biopsy results reported for all grades of cervical disease (≥ CIN 1)
Colposcopy sensitivity/specificity • Colposcopy performed following abnormal cytology
• Colposcopically directed cervical biopsy performed on all women
• Biopsy results reported for all grades of cervical disease (≥ CIN 1)
Symptom development among cancer patients • Stage-specific symptom development
• Representative cross-section of patients with cervical cancer at each stage 
including patients who may harbor occult cancers
➢ If unavailable, then rely upon expert opinion from the literatureBMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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PCR-based methods for the detection of HPV DNA were
therefore excluded from the review.
Also, the model separately simulates the natural histories
of HPV 6/11 and HPV 16/18 infections and focuses solely
on disease due to these HPV types. Thus, in deriving
model inputs, studies that provided data on the natural
history of HPV 16/18 disease were preferred over those
describing data for disease due to all high-risk (H-R) HPV
types, which in turn were preferred over those with data
for disease due to all HPV types (H-R and low-risk [L-R]
combined). A similar hierarchy was employed for select-
ing studies in the modeling of HPV 6/11 infection.
The combining of data into two groupings for types 6/11,
and 16/18, respectively, was performed due to a general
lack of published studies specifically describing the time
to progression of individual incident HPV types in the
development of disease at the time of our initial model
design. The few available studies with stratification by
HPV type combined reporting of results for HPV types 6/
11 and 16/18 [36,40,41]. In our own work, we have
begun to describe the natural history of individual HPV
types and have observed similar infection durations for
HPV 6 and 11, and HPV 16 and 18, respectively [42]. With
regard to disease progression, confidence intervals for
individual type progression rates have either been similar
and overlapping, or sample sizes too small regardless (in
the case of HPV 11) for meaningful comparisons between
paired types [43]. As additional data on single type infec-
tions are published, further refinements may become pos-
sible. Given that other HPV natural history models may
have alternate structures as compared to that of our model
[10,44], studies presenting data with other HPV type
dichotomies will also be briefly discussed.
Eradication of CIN with treatment • Representative study of CIN therapies used in practice if available
➢ If unavailable then select studies of LEEP (most common modality)
• Stratified reporting of outcomes by pre-treatment CIN grade
• Post-treatment follow-up of all women within 12 months via colposcopy and/or 
biopsy
• Definition of recurrent or residual disease as CIN 1 or more severe histology
Eradication of cervical cancer with treatment • Nationally representative or broad population-based studies of 5-year disease-
free survival by cancer stage
➢ If unavailable, then select nationally representative or broad population-based 
studies of 5-year relative survival by cancer stage
Eradication of genital warts with treatment • Representative study of genital wart treatments used in clinical practice
• Physician ascertained clearance following treatment for all subjects
Persistence of HPV following cervical disease eradication • Representative study of therapies used in practice if available
➢ If unavailable, then select studies of LEEP (most common modality) for CIN, 
and hysterectomy or radiation therapy for cervical cancer
• Histologic confirmation of disease pre-treatment and post-treatment 
(for exclusionary study purposes)
• HPV typing of pre- or post-treatment lesion tissue specimens or both
➢ If unavailable, then select studies with HPV typing of any cervical specimen
• Follow-up for all women within 6 months post-treatment
➢ If unavailable, then select studies with less prompt follow-up
• Colposcopy performed on all women post-treatment to assist in confirming 
disease eradication
Persistence of HPV following genital wart eradication • Representative study of genital wart treatments used in clinical practice
• Testing for HPV infection across a range of anogenital sites post-treatment 
(not just at the former wart site)
• Follow-up for all women within 6 months post-treatment
➢ If unavailable, then select studies with less prompt follow-up
Care seeking behavior for genital warts • Population-based studies of patients with genital warts, including both those who 
have, and who have not, chosen to seek physician care
➢ If unavailable, then rely upon expert opinion from the literature
CIN = Cervical intraepithelial neoplasia; HPV = Human papillomavirus; LEEP = loop electrosurgical excision procedure; PCR = Polymerase chain 
reaction
Table 2: Summary of Study Selection Criteria By Parameter Group (Continued)BMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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Interval of Follow-up
The model uses continuous mathematical functions to
estimate the instantaneous rates of progression and
regression of disease. In practice, however, all studies of
HPV disease natural history collect observations at dis-
crete time intervals, typically ranging from several months
to several years apart. Given the relatively active progres-
sion and regression of some facets of HPV disease within
a matter of months [45,46], differences in follow-up inter-
vals across studies or patients within a given study can
produce vastly different results regardless of differences in
underlying natural history [34].
For instance, suppose a woman developed an incident
CIN 1 lesion just prior to baseline, progressed to CIN 2 at
12 months and regressed to negative for HPV infection at
24 months. A study with observations at only baseline
and month 24 would conclude that this CIN 1 case
regressed to normal, whereas a two-year study with a 12
month observation interval would observe progression to
CIN 2, as well as subsequent regression. Given that many
U.S. women undergo routine Pap screening as frequently
as once a year [47], with the potential for disease detec-
tion, natural history studies with observation intervals less
frequent than every 12 months were excluded. Also
excluded were studies that did not characterize the timing
of progression and regression within uniform intervals
across all women.
A decision was also made to pre-specify a uniform crite-
rion across studies for the time point at which to assess
event rates. Some HPV natural history studies report the
regression or progression of CIN over a single year of total
follow-up [46,48]. while others track events across multi-
ple years [41,49]. Although studies with longer follow-up
might be expected to be more comprehensive in describ-
ing disease natural history, we chose to model annual
transition probabilities based on event rates observed dur-
ing the first 12 months of follow-up in each study for our
base case parameter estimates.
There were two main reasons for choosing a 12 month
horizon. First, for a number of natural history studies,
HPV typing data for lesions observed on follow-up are
unavailable, and as one looks over longer time horizons,
it may become increasingly likely that apparent "progres-
sion" to higher grade HPV disease, or persistence, will be
unrelated to the original HPV disease state of interest. For
instance, a recent study found that among 16–27 year old
U.S. women with incident HPV 6, 11, 16 and 18 infec-
tions who were observed to develop CIN during up to 36
months of follow-up, 50.4% had a lesion containing a dif-
ferent HPV type than that observed in the incident infec-
tion [43]. While it is not possible to completely eliminate
this source of bias in these types of HPV natural history
studies, it was felt that data on disease activity observed
during the first 12 months of follow-up would provide a
more reliable proxy for annual transition rates between
states. Second, estimated annualized risks of progression/
regression can become meaningless if computed at or
beyond the time point at which all potential transitions
occur. For instance, all incident HPV 6/11 infections were
observed to either progress or regress within 18 months in
a recent study [43]. Because a number of natural history
studies provide only a partial picture of overall transitions
(e.g., disease progression only), the uniform 12 month
interval was chosen for the primary analysis.
Where studies of HPV disease natural history with multi-
ple years of follow-up are available, we will also compare
the 12 month results across studies used in the base case
to those observed through the mean or median follow-up
time (if the mean is not reported). The choice of mean/
median follow-up time is based on the observation that
differential patient follow-up, as well as loss to follow-up,
can render estimates derived from the longest follow-up
times unstable. Unless otherwise noted, consistent with
prior studies [10,12,44], a simplifying assumption for
both estimations is that risks of progression and regres-
sion are generally constant over time.
Age-specific Natural History Modeling
We considered the issue of whether to model HPV infec-
tion and disease natural history on an age-specific basis,
or uniformly across age. Recent studies have failed to
demonstrate a difference with age in the rate of clearance
of HPV infection [50,51], however, less data are available
concerning the age-specific progression and regression of
CIN. A retrospective study by Konno et al. reported that
48% of untreated CIN 2/3 cases among women age 30–49
(n = 128) were observed to progress over time compared
to 32% of cases among women age 50–79 (n = 66), how-
ever, the difference in rates with age was not statistically
significant [52]. In the absence of definitive data demon-
strating age-specific variation in the progression and
regression of CIN (or HPV), we therefore elected to apply
constant risks across age.
Risks vs. Rates
Nearly all HPV natural history studies report a risk of pro-
gression or regression of disease, rather than a rate. Most
models, however, use rates to express health state transi-
tions. For ease of reference with respect to the original
sources, we describe data selected from the literature in
the form of a risk (proportion) in this review, and for our
cost-effectiveness model [14]. These risks may be con-
verted to rates using the formula rate = -[ln(1-p)]/t, where
p is the risk or proportion and t is the follow-up time in
years.BMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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Table 3: Epidemiologic Natural History Model Parameters
Parameter Estimate
Progression in the presence of HPV 16/18, % per year
Normal to CIN1[43] 9.4
Normal to CIN 1 to CIN 2 [41,43] 5.8
Normal to CIN 1 to CIN 2 to CIN 3 [41,43] 3.5
CIN1 to CIN 2* 13.6
CIN 2 to CIN3 (severe dysplasia) [49,65] 14.0
CIN 3 (severe dysplasia) to CIN 3 (CIS) [49,68] 43.0
CIN 3 (CIS) to LCC 4.1
LCC to RCC [7,9,22,23] 10.0
RCC to DCC [22] 30.0
Progression in the presence of HPV 6/11, % per year
Normal to CIN1 [43] 8.5
Normal to CIN 1 to CIN 2 [43] 1.9
Normal to CIN 1 to CIN 2 to CIN 3 [43,78,79] 0.0
CIN 1 to CIN2 * 0.0
Normal to genital warts [41] 57
Mean HPV infection duration with CIN absent, years
HPV 16/18 infection [42] 1.2
HPV 6/11 infection [42] 0.7
Duration of acquired immunity following HPV infection 10 years to Lifelong
Regression of HPV 16/18+ disease, % per year
CIN1 to Negative/HPV 16/18 [40]* 32.9
CIN 2 to Negative/HPV 16/18 [49,65,85] 21.0
CIN 2 to CIN 1 [65] 13.3
CIN 3 (severe dysplasia) to Negative/HPV 16/18 [49] 11.0
CIN 3 (severe dysplasia) to CIN 1 [49,65] 3.0
CIN 3 (severe dysplasia) to CIN 2 [49,65] 3.0
Regression of HPV 6/11+ disease, % per year
CIN1 to Negative/HPV 6/11* 55.2
Genital warts to Negative/HPV 6/11 [41,88] 87.5
Age and stage-specific cervical cancer mortality, 1997–2002, % per year [69]
for LCC
15–29 years 0.7
30–39 years 0.6
40–49 years 0.8
50–59 years 1.9
60–69 years 4.2
≥ 70 years 11.6
for RCC
15–29 years 13.4
30–39 years 8.9
40–49 years 11.0
50–59 years 10.1
60–69 years 17.6
≥ 70 years 28.6
for DCC
15–29 years 42.9
30–39 years 41.0
40–49 years 46.7
50–59 years 52.7
60–69 years 54.6
≥ 70 years 70.3
CIN = cervical intraepithelial neoplasia; CIS = carcinoma in situ; DCC = distant cervical cancer; HPV = human papillomavirus; LCC = localized 
cervical cancer; RCC = regional cervical cancer
*R. Insinga, unpublished data.BMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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Results
Epidemiologic Natural History
Table 3 summarizes the data sources, parameters and val-
ues for the HPV epidemiologic natural history model var-
iables which will now be reviewed.
Progression of HPV 16/18 infection to Histologically Detectable CIN
HPV 16/18 infection to CIN 1
Only one prior study was found estimating the incidence
of CIN 1 following HPV 16/18 infection [43]. The 12
month risk of progression of incident HPV 16/18 infec-
tions (n = 204) to histologically detectable CIN 1 was esti-
mated to be 9.4% in a study by Insinga et al., one of the
authors of this review. In that study, women underwent
cervical swab PCR and thin-layer Pap testing at approxi-
mate 6 month intervals through 48 months of follow-up.
The study protocol mandated that women with cytologic
evidence of HSIL or repeated tests showing LSIL, ASCUS
or AGC undergo colposcopy. However, some women
were referred for colposcopy more frequently than
required based on local standards of care. All women
attending the month 48 trial visit were referred for colpos-
copy, with cervical biopsies performed if a lesion was sus-
pected. Cervical biopsy specimens were typed for
individual HPV types by PCR. If analyzed through the
study mean follow-up time of 21.9 months, the cumula-
tive risk of progression to CIN 1 was 14.6%, approxi-
mately equivalent to an annual progression rate of 8.3%.
For the purposes of this review, a strength of the study was
the focus specifically on HPV 16/18 infections and the
correlation between HPV types observed in infection and
CIN lesions. However, a limitation was that not all
women in the study underwent cervical biopsy, with the
potential for missed lesions.
Although no additional studies of CIN 1 incidence were
found in the literature specific to HPV 16/18 infection,
Hoyer et al. [53,54], followed up women with a positive
H-R HPV test at baseline with colposcopy and biopsy
within 8 months and reported CIN 1 cases detected. How-
ever, it was not possible to determine whether prevalent
CIN disease was already present at baseline and if the HPV
type observed at baseline was the same as that of the CIN
lesions detected during follow-up.
HPV 16/18 infection to CIN 2/3
While some women with incident HPV 16/18 infections
will be found on subsequent histology to have CIN 1 in
natural history studies, there are also instances where the
transition from HPV to CIN 1 to CIN 2 may occur before
an initial histologic specimen is taken, and a CIN 1 diag-
nosis is never observed [36,55,56]. In some cases, there
will even be rapid enough progression from incident HPV
infection to CIN 1 to CIN 2 to CIN 3 to render CIN 3 the
first detectable CIN state for the purposes of modeling.
The 12-month risk of progression of incident HPV 16/18
infection to CIN 2 was estimated to be 5.8%, and to CIN
3 was estimated to be 3.5%, based on studies by Winer et
al. and Insinga et al. [41,43]. In the Winer et al. study,
women underwent Pap screening, colposcopic evaluation
and cervical swab HPV testing and typing at 4 month
intervals. Women with cytologic or colposcopic evidence
of HSIL, or repeated LSIL or equivocal cytology, were
biopsied. The combined incidence of CIN 2–3 within 12
months following an incident HPV 16/18 infection (n =
60) was observed to be ~12%. Five cases of CIN 2 and four
cases of CIN 3 had HPV 16/18 infection detected on a cer-
vical swab at the visit prior to biopsy, with no difference
observed in the median time from incident HPV infection
to incident CIN 2 vs. CIN 3. Annual risks of progression to
CIN 2 (12%*5/9 = 6.7%) and CIN 3 (12%*4/9 = 5.3%)
were derived from these figures. In the Insinga et al. study,
described previously, the 12 month risk of progression to
CIN 2 was 4.8% and to CIN 3 was 1.7% [43], which were
averaged with the Winer et al. data to yield overall risks of
progression.
The Winer and Insinga studies also included data on inci-
dent HPV 16/18 infections through a mean follow-up of
38.8 and 21.9 months respectively, with respective cumu-
lative risks of progression to CIN 2/3 during those time
intervals of approximately 27.2% and 11.5%, or 9.4% and
6.5%, when annualized [41].
The Winer study has a number of strengths for assessing
HPV natural history with respect to CIN 2/3 development
relative to other analyses [36,53], including the identifica-
tion of type-specific incident HPV infections, frequency of
follow-up, and PCR testing used for HPV detection and
typing. A few limitations of the study, in the context of the
present review, were that all CIN 2–3 biopsy results,
regardless of underlying HPV type in the lesion, were used
in estimating incidence rates of CIN 2–3 following HPV
16/18 infection, some women with an impression of LSIL
on colposcopy or who appeared normal who were never
biopsied may have harbored underlying CIN 2–3, and
some women may have had CIN 1 detected prior to their
CIN 2/3 diagnosis [41]. The Insinga study overcame the
first and last of these limitations, and the colposcopic
threshold for biopsy was lower (LSIL vs. HSIL), however,
colposcopy was less routinely performed than in the
Winer study. Other published data overcoming these lim-
itations were not found.
Progression of HPV 16/18-positive CIN and Cancer
HPV 16/18-positive CIN 1 to CIN 2
No studies were found describing the 12 month progres-
sion of HPV 16/18-positive CIN 1 to CIN 2. Three studies
reported data on the 12 month progression of biopsy-con-
firmed CIN 1 to CIN 2 without regard to HPV typeBMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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[48,49]. Twelve month risks of progression across the
three studies averaged ~7%. However, based on a review
of U.S. studies reporting HPV type-specific PCR testing
results for CIN 1 biopsy specimens, approximately 15% of
all CIN 1 cases are estimated to be associated with HPV
16/18 infection, with the remainder associated with other
HPV types or testing negative for HPV (~18%) [43,58-61].
Furthermore, a similar review of U.S. studies of biopsy-
confirmed CIN 2–3 found that 59% of specimens tested
positive for HPV 16/18 infection [58-62], suggesting that
HPV 16/18 positive CIN 1 is more likely to progress to
CIN 2 than CIN 1 due to other HPV types. As such, studies
reporting data across all CIN 1 cases were deemed to be of
low adequacy for assessing the natural history of CIN 1
due to HPV 16/18 infection.
Since type-specific data were not found in the literature,
we instead examined data from Merck's F.U.T.U.R.E. I and
II HPV vaccine phase III trials [63]. Data were analyzed for
placebo arm women, age 16–23 at baseline, who devel-
oped incident HPV 16 or 18 infection during the course of
follow-up as detected through cervical swabs, and who
subsequently were detected with incident biopsy-con-
firmed CIN 1 that tested positive on Thinsection PCR test-
ing for HPV 16 or 18 (R. Insinga, unpublished data).
Women with incident infection for a specific HPV type
were required to be sero-negative and PCR negative for
that type at baseline, and to qualify as an incident CIN 1
cases due to a particular HPV type there must have been
no biopsy result with higher grade CIN or cancer testing
positive for that HPV type prior to the CIN 1 diagnosis.
Once CIN 1 was diagnosed, women were followed up
with repeat cytology at 6 month intervals, with repeat col-
poscopy and biopsy if cytologic abnormalities persisted.
Four women with persistent CIN 1 on 2–4 consecutive
biopsies were treated during the course of follow-up, and
evaluated as censored at the time of treatment. Among 64
women with incident CIN 1 biopsy specimens testing pos-
itive for HPV 16/18 infection, the 12 month risk of pro-
gression to HPV 16/18 positive CIN 2 was estimated to be
13.6%. None of the women progressed directly from CIN
1 to CIN 3. There were insufficient data beyond 12
months follow-up for longer-term analyses.
A limitation of the Merck trial-based analysis is that gen-
erally only women with continued cytologic abnormali-
ties during the course of follow-up underwent repeat
colposcopy and biopsy. Also, if the small number of
women with persistent CIN 1 who were treated differed in
their natural history from those with persistent CIN 1 who
were untreated at the same follow-up time, the results
could be affected. The finding that the 12-month risk of
progression of CIN 1 due to HPV 16/18 (13.6%) was
higher than that averaged from analyses reporting data for
all CIN 1 cases (~7%) is consistent with the greater known
risk of high-grade CIN and cancer due to these types
[41,64].
HPV 16/18-positive CIN 2 to CIN 3 (severe dysplasia)
No studies were found in the literature review document-
ing the 12-month progression of CIN 2 due to HPV 16/18
infection to CIN 3 or for any higher grade of cervical dis-
ease due to HPV 16/18 infection. For U.S. women in the
placebo arms of F.U.T.U.R.E. I and II, it was estimated that
54% of initial CIN 2 biopsies (n = 37), that were not pre-
ceded by a higher grade of CIN or cancer, tested positive
for HPV 16/18 infection. Thus, studies of disease regard-
less of HPV type status are likely to be more generalizable
to HPV 16/18 disease natural history for CIN 2 than CIN
1.
Two studies were identified reporting a 12 month risk of
progression of biopsy confirmed CIN 2 to CIN 3 (severe
dysplasia). In the first, by Kataja et al. (n = 70), women
with CIN 2 on punch biopsy at baseline were followed up
with Pap screening, colposcopy and biopsy at 6 month
intervals, with treatment of disease if progression to carci-
noma in situ (CIS) was observed on biopsy [49]. The sec-
ond, by De Aloysio et al., was a clinical trial of interferon-
β treatment of CIN 2 [65]. Only data for placebo arm par-
ticipants (n = 15) were included in the present review, as
these women were not treated unless progression to CIN
3 was observed on biopsy. Similar to the Kataja study,
women underwent colposcopy and biopsy at 6 month
intervals during follow-up. Progression in both studies
was defined based on a biopsy confirmed diagnosis of
CIN 3, with ~8% of women in the Kataja study and 20%
of women in the De Aloysio study progressing to CIN 3
within 12 months. Averaging across the two studies
yielded an annual risk of progression of 14%.
The mean follow-up time in the Kataja study was 3.75
years and in the De Aloysio study was 2.0 years. Progres-
sion to CIN 3 through the mean follow-up time in the
Kataja study was ~23% and in the De Aloysio study was
33%. The corresponding estimated annual proportion
progressing through the mean follow-up times were 7%
and 18% respectively (mean 12%), similar to the esti-
mates derived from the 12 month follow-up data. A limi-
tation of both analyses in the context of the present review
is that they did not report data specifically for HPV 16/18
disease and hence did not verify that CIN 3 cases observed
over time were due to the same HPV types found in the
CIN 2 lesions.
HPV 16/18-positive CIN 3 (severe dysplasia) to CIN 3 (CIS)
The histologic diagnosis of CIN 3 may be sub-divided into
the categories of severe dysplasia, and CIS, representing
conversion of more than 2/3 but less than the full thick-
ness of the cervical epithelium, and the full thickness ofBMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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the epithelial layer, but without signs of invasion into the
stroma, respectively [66,67]. This distinction was made in
the model as reflective of the manner in which data were
reported in prior natural history studies of CIN 3 disease,
however it is also acknowledged that in clinical practice
these classifications may be used interchangeably as dis-
tinctions can be subtle.
A study by Westergaard et al. analyzed data for 49 women
with biopsy confirmed CIN 3 (severe dysplasia) [68].
Women were followed up with colposcopically directed
biopsies and cervical smears at 3 and 9 months post-base-
line, with repeat cervical biopsies at least once per year
thereafter, if persistent disease was observed. Women pro-
gressing to CIS were treated with conization, however,
none of the women with persistent severe dysplasia were
treated within 12 months. Over a 12 month time period,
47% of women with severe dysplasia progressed to CIS (n
= 22) or microinvasive carcinoma (n = 1). The Kataja
study, described previously, reported a 12 month risk of
progression for severe dysplasia (n = 29) of ~38% [49].
Averaging across the two studies yields a 12 month risk of
progression of 43%.
Progression over time was reported through 21 months
follow-up in the Westergaard study, with 1 woman treated
for severe dysplasia during that period. However, as more
women were treated following this time point (with
median total follow-up time of 40 months) further data
over time were not reported. Using data through 21
months from the Westergaard study, and 45 months from
the Kataja study, yields an annual proportion progressing
to CIS of 38% and 40% respectively, similar to the 12
month figures. Limitations of these analyses are similar to
those described for progression from CIN 2 to CIN 3
(severe dysplasia).
HPV 16/18-positive CIN 3 (CIS) to Localized Cervical Cancer
The literature review did not reveal a study meeting the
pre-defined eligibility criteria documenting the 12 month
progression of untreated CIS to localized invasive cervical
cancer (LCC) [International Federation of Gynecology
and Obstetrics (FIGO) Stage I]. Based on the limited data
available, and calibration to population data for cervical
cancer incidence, other cost-effectiveness models of HPV
vaccination have assumed a very low rate of annual pro-
gression from CIN 2/3 to invasive cervical cancer [7-9].
For instance, Goldie et al. reported a 20-fold range
dependent upon a woman's age, varying from as low as
0.2%, to up to 4.0% among women over age 65 [7], while
Kulasingam et al. and Sanders et al. have referenced
annual transition probabilities of 3–5% with no age-
dependency of progression rates [8,9,12].
As noted previously, prior cost-effectiveness analyses have
modeled the progression of CIN 2/3 to LCC, rather than
CIS to LCC and the existing literature is insufficient for
precisely determining the risk of progression to LCC from
either state. In the absence of literature-based data, we
therefore undertook a strategy of calibrating the model to
U.S. cervical cancer rates observed with [47,69], and with-
out [70] cytologic screening. This led to the selection of an
overall average 12-month risk of progression from CIS to
LCC of 4.1%, represented by two linked compartments
(labeled CIS1 and CIS2) with progression rates of 5% and
18% respectively. The low overall annual risk of progres-
sion is consistent with the long interval observed between
the peak age of HPV infection [71] and cervical cancer
detection [70], estimated to be 2–3 decades in duration
on average [72].
The decision to divide the CIS state into two compart-
ments was motivated by a comparison of model output
with observed data on cervical cancer incidence [69,70].
The model utilizes an exponential distribution to model
progression (and regression) which, like Markov proc-
esses featured in other cost-effectiveness models [7-9] is
characterized by a constant transition rate over time. As
seen in the example in Figure 3, with a constant progres-
sion rate, the largest proportion of individuals newly
entering a given health state will progress to a subsequent
health state during the first year, due to a declining
denominator in the initial health state during each subse-
quent year.
For health states of shorter duration, with relatively high
rates of progression and/or regression, such as for HPV
infection and CIN (up to CIS), this formulation may rea-
sonably describe natural history, as time in the health
state will be relatively brief regardless of the distributional
shape applied to the observed rates. However, for health
states of relatively long duration, one may generate results
in which individuals transition to another health state
much more quickly than is consistent with the natural his-
tory of disease. Figure 4 illustrates an identical average risk
of progression over a 25 year period as that depicted in
Figure 3, however, the distribution has now been ren-
dered more normally distributed, with the peak propor-
tion of the initial cohort now progressing during year 10
(7.5%).
To gain insight into whether a distribution more similar
to Figure 3 or to Figure 4 would be most appropriate for
modeling the progression of CIS to invasive cervical can-
cer, we compared age-specific rates of CIN 2/3 to those
observed for cervical cancer. From recent population data,
the peak incidence of CIN 2/3 has been observed among
screened women age 25–29, with a steep decline in inci-
dence thereafter [73,74]. However, data for cervical cancerBMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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incidence in Connecticut prior to screening shows a peak
incidence among women age 50–59 during the 5-year
period from 1940–44 [75]. These age trends are illustrated
using data from Insinga et al. [73] and Laskey et al. [75],
respectively, in Figure 5.
If one were to utilize a distribution with a constant risk of
progression, as depicted in Figure 3, then with the major-
ity of CIN 2/3 cases observed by the late 30 s, if not at an
earlier age, one would expect the peak incidence of cervi-
cal cancer to be observed around that time. Instead, how-
ever, the peak age of cervical cancer incidence in the
absence of screening was observed to be in the 50 s in
Connecticut [75], as well as in a separate study of cancer
incidence among women living in 10 U.S. cities con-
ducted in 1947 [76,77], suggesting that the largest propor-
tions of women progressing to cervical cancer are likely
doing so some years after the women have initially
entered the CIS state. This is more characteristic of Figure
4, in which a relatively smaller proportion of women
progress very quickly to cervical cancer, (as would be dis-
proportionately observed among women diagnosed with
cervical cancer following the introduction of screening),
with a relatively larger fraction of women progressing to
cervical cancer after a number of years (whose cancers
would be much more likely to be detected and prevented
in the pre-invasive phase with screening).
The division of the CIS state into two compartments was
designed to approximate this latter distributional shape,
with the relatively slower annual risk of progression from
CIS1 to CIS2 (0.05), followed by a faster risk of progres-
sion from CIS2 to LCC (0.18), allowing for a delay in the
time point of peak progression of CIN 3 to LCC (by 8–10
years) so as to better fit cervical cancer natural history data
[70]. Under these assumptions, in the absence of screen-
ing and hysterectomy, the model estimates a peak cervical
cancer incidence due to HPV 16/18 infection of 43.6 per
100,000 among women age 50–59. This compares to
peak rates of cervical cancer incidence, regardless of HPV
type, of 50–90 per 100,000 among women age 50–59,
observed in Connecticut and 10 U.S. cities prior to the
Annual Proportion of An Incident Cohort Progressing Under An Exponential Distribution Figure 3
Annual Proportion of An Incident Cohort Progressing Under An Exponential Distribution. In this example, an 
incident cohort at year 0 progresses to a subsequent health state at an annual rate of 0.078, corresponding to a constant annual 
risk of 7.5%. This results in 7.5% (1*.075) of the original cohort progressing in year 1. By the start of year 10, 49.6% of the orig-
inal cohort remains in the initial health state, and only 3.7% (.496*.075) progress during year 10. Regardless of the value for risk 
chosen, the absolute proportion progressing will be highest during year 1 and decline steadily with time. For simplicity, mortal-
ity and disease regression are not modeled here.
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introduction of screening [75]. The model incidence falls
near the lower end of this range because approximately
70% of all U.S. cervical cancers are caused by HPV 16/18
infection [16].
HPV 16/18-positive LCC to Regional and Distant Cervical Cancer
As was the case for CIS, no studies providing natural his-
tory data on progression across cervical cancer stages were
found that met the review eligibility criteria. For LCC to
regional cervical cancer (RCC) [FIGO Stages II-III], we
modeled an annual progression risk of 10%, and for RCC
to distant cervical cancer (DCC) [FIGO Stage IV] a risk of
30%, within the ranges assumed in prior HPV natural his-
tory models [7,9,22,23]. Progression rates within cervical
cancer states were modeled within a single compartment,
as they were estimated to be of significantly shorter dura-
tion than time spent with CIN3-CIS [23].
Progression of HPV 6/11 infection to Histologically Detectable CIN 
and Anogenital Warts
HPV 6/11 infection to CIN 1
The Insinga study described previously was the only anal-
ysis meeting review eligibility criteria found to describe
the annual risk of clinically diagnosed CIN of any grade
following HPV 6/11 infection [43]. The Hoyer study
reported the risk of CIN among women with H-R HPV
infection [53], however, data were not found in that or
other studies for women with L-R HPV infection.
In the Insinga analysis, from among 116 women with
incident HPV 6/11 infections, 8.5% were diagnosed with
biopsy-confirmed CIN 1 testing PCR-positive for HPV 6/
11 infection within 12 months [43]. Through a mean fol-
low-up of 20.6 months, 12.3% of women progressed to
CIN 1, for an annualized risk of 7.4%.
HPV 6/11 infection to CIN 2/3
In the Insinga study, two woman with incident HPV 6/11
infections were observed to have a CIN 2 lesion testing
PCR positive for HPV 6/11 infection within 12 months for
Illustration of Normally Distributed Progression Over Time In An Incident Cohort Figure 4
Illustration of Normally Distributed Progression Over Time In An Incident Cohort. In this example, an identical 
average annual rate (0.078) and risk (7.5%) of progression over a 25 year period has been modeled as in figure 3. However, 
through a transformation, the absolute risk of progression over time has now been rendered normally distributed (with stand-
ard deviation of 6) with the largest proportion of individuals now progressing near year 13 rather than year 1.
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a progression risk of 1.9% [43]. No additional progression
was observed through 36 months of follow-up. No HPV
6/11 positive CIN 3 cases were observed through 36
months of total follow-up. A review of U.S. studies per-
forming HPV typing of biopsy-confirmed CIN 3 lesions
did not reveal any cases testing positive for HPV 6 or HPV
11 infection [43,78,79] and these types have not been
observed more frequently than among control women in
cervical cancer biopsy specimens [64]. We therefore chose
to assume that HPV 6/11 infection did not progress
beyond CIN 2.
HPV 6/11-positive CIN 1 to CIN 2
In the F.U.T.U.R.E. study analyses described previously,
there were 25 incident cases of CIN 1 testing PCR positive
for HPV 6/11, none of which progressed to CIN 2 during
the course of follow-up (R. Insinga, unpublished data).
The model transition probability for this parameter was
therefore set to zero.
HPV 6/11 infection to Anogenital Warts
In the Winer study described previously, anogenital warts
were detected within 12 months in ~57% of women with
incident HPV 6/11 infection [41]. Through the mean fol-
low-up time of 38.8 months, anogenital warts were
observed in 66.2% of women with incident HPV 6/11
infection, which would translate to an annual risk of pro-
gression of 28.5%. However, no new warts were observed
among women with incident HPV 6/11 infection during
the final 12 months prior to the mean follow-up time, and
the 12 month progression figure may therefore be more
reliable if the totality of progression occurs soon after
infection. The Winer study did not show progression of
HPV 16/18 infection to genital warts within 12 months
time and we assumed that these types did not progress to
warts [41].
Duration of HPV 6/11 and HPV 16/18 infections in the Absence of 
CIN
Duration of HPV 16/18 Infections
The duration of HPV infection, in the model, refers to the
persistence of type-specific HPV infection up to the point
of progression to clinically detectable CIN, or clearance of
HPV infection. Only two studies were identified reporting
the mean duration of incident HPV 16/18 infections
[42,80]. The first, by Richardson et al., censored women at
the time of colposcopy, rather than truncating infection
duration upon the detection of CIN, and followed women
for less than 2 years post-infection, which likely underes-
timated mean duration due to the censoring of a signifi-
cant fraction (~50%) of persistent HPV infections at the
conclusion of follow-up [80]. The second, by Insinga et
al., truncated infection duration at the time of CIN devel-
opment and followed women for up to 3 years post-infec-
Incidence of CIN 2/3 Detected Through Screening and Cervical Cancer Incidence Prior to Screening Figure 5
Incidence of CIN 2/3 Detected Through Screening and Cervical Cancer Incidence Prior to Screening. Rates are 
per 100,000 women undergoing routine cytologic screening for CIN 2/3, and per 100,000 women for cervical cancer. The peak 
incidence of invasive cervical cancer is observed approximately 25–30 years later than for CIN 2/3. Sources: CIN 2/3 inci-
dence among screened women (Kaiser Permanente Northwest Health Plan, Portland, Oregon, 1998–2002) [73], Cervical can-
cer incidence among unscreened women (Connecticut, 1940–1944) [73].
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tion, with 2.5% of infections persistent in the absence of
CIN beyond that time point [42]. The latter study esti-
mated a mean duration of HPV 16/18 infection of 1.2
years and this figure was selected for the model.
Duration of HPV 6/11 Infections
From the Insinga study described previously [42], the
mean duration of incident HPV 6/11 infections was esti-
mated to be 0.7 years.
Existence and duration of acquired immunity following HPV infection
Nearly all previous HPV natural history models used in
policy analyses have assumed that women infected with
HPV have no protection against subsequent re-infection
[7-9,22,24,26]. Data on the existence of elevated antibod-
ies following type-specific HPV infection have been
reported [81], however, the potential degree and duration
of subsequent acquired immunity to HPV infection are
unknown. Several recent clinical trials of HPV vaccines
have demonstrated that antibody responses mounted to
HPV virus-like particles can provide protection against
HPV infection for a period of at least several years
[19,20,22]. It would thus seem plausible that natural
infection with HPV may also confer some degree of
immunity, although available data are insufficient for pre-
cise estimation [83,84]. We therefore chose to vary the
duration of assumed acquired immunity following HPV
infection from 10 years to lifetime in the model.
Regression of HPV 16/18 positive CIN
HPV 16/18-positive CIN 1 to Negative/HPV 16/18
The regression of CIN 1 lesions testing PCR positive for
HPV 16/18 infection was examined in a study of placebo
arm enrollees from the F.U.T.U.R.E. I and II trials as
described previously. Women with incident CIN 1 lesions
were presumed to have regressed if they had at least 2 con-
secutive negative cervical cytology or histology specimens
following diagnosis. Within 12 months, 45.7% of inci-
dent HPV 16/18 positive CIN 1 cases (n = 64) were esti-
mated to have regressed.
A study by Sastre-Garau et al. reported that ~18% of prev-
alent CIN 1 lesions testing positive for HPV 16/18 infec-
tion (n = 28) regressed within 12 months [40]. The
interval between follow-up visits was generally longer
than in the F.U.T.U.R.E. trials, with women observed to
have biopsy-confirmed CIN 1 at baseline undergoing a
repeat colposcopy and biopsy at 10–12 months and again
at approximately 2 years. Regression was defined to occur
if CIN was not observed on follow-up colposcopy and
biopsy. Averaging results across the two studies yielded an
average 12 month risk of regression of HPV 16/18 positive
CIN 1 of 32.9%.
Data beyond 12 months were not available from the trial
analyses, but over a median follow-up of 24 months, the
annual risk of regression in the Sastre-Garau study was
approximately 19%. A limitation of both analyses is that
cervical HPV typing results were not available during the
follow-up periods, with the exception of instances in
which histologic specimens were obtained. Thus it is pos-
sible that some women with evidence of persistent abnor-
mal cytology/histology harbored disease due to other
HPV types following the regression of their HPV 16/18
positive CIN 1 lesions, which may render the reported
estimates of disease regression somewhat conservative.
Several additional studies meeting review eligibility crite-
ria estimated the risk of regression of CIN 1 without
regard to HPV type [48,49,57,85]. The literature review
did not yield data on the proportion of women with
regressed CIN who remain positive for HPV infection fol-
lowing the disappearance of clinically detectable CIN. A
figure of 50% was therefore used as a base case assump-
tion, with variation in sensitivity analyses.
HPV 16/18-positive CIN 2 to Negative/HPV16/18
As no studies were identified reporting data for the regres-
sion of HPV 16/18-positive CIN 2 lesions, we utilized data
from three studies reporting data across all biopsy-con-
firmed CIN 2 cases. The first two studies, by Kataja and De
Aloysio, have been described previously and reported 12
month risks of regression of CIN 2 to HPV/normal of ~2%
and 40% respectively [49,65]. In the Kataja study, evi-
dence of regression required a negative result on Pap
smear, colposcopy and biopsy at a given visit, while in the
De Aloysio study regression was based on the absence of
CIN on biopsy only. A third study by Matsumoto et al.
reported that ~21% of CIN 2 lesions (n = 36) regressed
within 12 months [85]. In the Matsumoto study, women
with biopsy confirmed CIN 2 at baseline were followed at
3–6 month intervals with cytology and colposcopy.
Regression was based on negative colposcopy and at least
2 consecutive negative Pap smears. Averaging data across
the three studies produced a 12-month risk of regression
of CIN 2 to normal/HPV of 21%.
The mean or median follow-up time was not reported in
the Matsumoto study, however, the mean annual risk of
regression through the mean follow-up times in the Kataja
and De Aloysio studies were 15% and 23% respectively
[49,65]. Limitations of the studies are similar to those
described for studies reporting data on the regression of
CIN 1.
HPV 16/18 positive CIN 2 to CIN 1
Of the three studies just described, only that of De Aloysio
also reported on the regression of CIN 2 to CIN 1 over
time. In addition to the group regressing to normal/HPV,
another 13.3% of women with CIN 2 in that studyBMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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regressed to CIN 1 within 12 months [65]. This figure was
11% through the mean follow-up time.
HPV 16/18 positive CIN 3 (severe dysplasia) to Negative/HPV 16/18
The only study meeting the review eligibility criteria for
the regression of CIN 3 (severe dysplasia) was that of
Kataja [49]. In that analysis, the 12 month risk of regres-
sion of severe dysplasia to normal/HPV was ~11%.
Through the mean follow-up time the figure was ~10%.
HPV 16/18 positive CIN 3 (severe dysplasia) to CIN 2 or CIN1
The Kataja study did not report data for the regression of
severe dysplasia to CIN 2 or CIN 1. However, as was the
case for CIN 2, in practice such regression is likely to occur
[65]. In the absence of available data, we assumed that the
ratio of CIN 3 regressing to Negative/HPV 16/18 versus
lower grade CIN was similar to that observed for CIN 2
(1.6:1). This resulted in an estimated regression of CIN 3
to CIN 2 and CIN 1 over 12 months of ~6%, which was
divided evenly into 3% to CIN 2 and 3% to CIN 1. Disease
progressing beyond severe dysplasia in the model was
assumed not to regress.
Regression of HPV 6/11 positive CIN and anogenital warts
HPV 6/11-positive CIN 1 to Negative/HPV 6/11
The study utilizing F.U.T.U.R.E. I and II trial data was the
only analysis identified examining the regression of CIN 1
testing positive for HPV 6/11. The 12-month risk of
regression was 55.2% (R. Insinga, unpulished data).
HPV 6/11-positive Anogenital Warts to Negative/HPV 6/11
No studies were found documenting the 12 month risk of
regression of anogenital warts in the absence of treatment.
Although a number of clinical trials have reported wart
clearance rates for patients receiving placebo, most have
featured follow-up of 3 months or less, and included high
proportions of patients with extensive, recalcitrant and
previously treated warts [86,87]. Only one study, by Fried-
man-Kien, was found to report longer-term data for previ-
ously untreated genital wart patients [88]. In that analysis,
3 of 8 (37.5%) previously untreated genital wart patients
were free of their warts at approximately 20 weeks follow-
up. Annualizing results from this small sample yields a
12-month clearance probability of 71%.
However, in practice, individuals with the largest and
most extensive warts may seek immediate treatment, and
natural clearance rates may be even higher among those
patients not seeking physician care. Considering those
patients who are treated, the Winer study described previ-
ously, reported that 75% of women with incident warts
undergoing treatment cleared the warts within 8.0
months [41]. Data through 12 months of follow-up were
not reported. However, assuming a constant proportional
hazard, the Winer results would convert to a 12 month
proportion regressing of 87.5%. Other recent data on inci-
dent anogenital wart clearance with a similar length of fol-
low-up in females or in males were not found. In the
absence of more suitable data, a 12 month probability of
clearance of 87.5% was estimated both for those warts
that are treated and those for which treatment is not
sought. A population-based study of wart patients in the
United Kingdom noted a similar proportion of male and
female patients receiving treatment had cleared their warts
within 3 months [89]. We therefore assumed that ano-
genital wart clearance occurred at a similar rate in males
and females.
Cervical Cancer Mortality (As a % of women within each cervical 
cancer stage and age grouping)
No studies were found estimating age- and stage-specific
annual mortality rates among a representative sample of
unscreened women with cervical cancer, as any such anal-
ysis would be fraught with ethical and methodological
difficulties. As an approximation, data from the Surveil-
lance Epidemiology and End Results Program (SEER) for
1997–2002 were used to estimate the 12 month excess
risk of mortality due to cervical cancer, by age group and
stage [69]. Excess risk of mortality due to cervical cancer is
estimated by SEER through a comparison of age-specific
mortality among women with cervical cancer to that
observed among women in the same age groups in the
general population [90]. Because cervical cancer mortality
is highest during the first 12 months following diagnosis
[90] use of the 12 month risks allows for the estimation of
an average mortality rate in the absence of treatment that
is higher than that estimated with treatment, as will be
described in a subsequent section. Other data sources for
cervical cancer mortality have been used in adaptations of
our model to country settings of Taiwan [91] and Mexico
[92].
Clinical Diagnosis and Treatment
Table 4 summarizes clinical diagnostic and treatment var-
iables used in the model. As noted in the Methods, certain
clinical parameters (i.e., rates of Pap screening/coverage,
rates of hysterectomy) would be expected to vary by coun-
try. As in prior reviews of HPV natural history and clinical
impact for infectious disease modeling [22,26], it would
impractical to attempt to describe these parameters for
every country in the world here. Consistent with our
recently developed model [14], parameters most likely to
vary by country are described for the U.S. population,
however data source selection issues may also be applica-
ble to other settings. We also reference data sources used
in adaptations of our model to selected other country set-
tings. Unless otherwise noted, type-specific HPV disease
data were unavailable for clinical diagnostic and treat-
ment variables.BMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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Hysterectomy For Non-HPV-related Conditions
Age-specific hysterectomy rates were modeled based on
1994–1999 data reported from the U.S. National Hospital
Discharge Survey [93]. Other data sources for hysterec-
tomy rates have been used in forthcoming adaptations of
our model to country settings of the United Kingdom
[94], Taiwan [95] and Mexico (Unpublished data. Insti-
tuto Mexicano de Seguridad Social, D.F., Mexico, 2004).
Utilization of Cytology Screening
Nationally representative data on cervical cancer screen-
ing are based on self-reported behavior, which has been
Table 4: Clinical diagnosis and treatment parameters
Parameter Parameter estimate
Hysterectomy for non-HPV-related conditions, % per year [93]
15–24 years 0.02
25–29 years 0.26
30–34 years 0.53
35–39 years 0.89
40–44 years 1.17
45–54 years 0.99
≥ 55 years 0.36
Cervical cytology screening, % per year (excluding those with hysterectomy) [47]
10–14 years 0.6 (0.6)
15–19 years 21.0 (21.0)
20–24 years 44.6 (44.8)
25–29 years 60.4 (61.6)
30–34 years 52.4 (54.9)
35–39 years 46.0 (50.5)
40–44 years 41.0 (48.1)
45–49 years 39.1 (49.1)
50–54 years 38.0 (51.1)
55–59 years 33.2 (46.7)
60–64 years 29.4 (42.5)
65–69 years 26.2 (38.9)
70–74 years 19.4 (29.6)
75–79 years 12.9 (20.1)
80–84 years 7.0 (11.1)
85+ 3.4 (5.5)
Women never screened, % 5.0
Liquid-based cytology sensitivity, %
for CIN 1 [114] 28
for ≥ CIN 2/3 [115] 59
Liquid-based cytology specificity, % [114,115] 94
Colposcopy sensitivity, % [117] 96
Colposcopy specificity, % [117] 48
Symptom development, % per year
for LCC 4
for RCC 18
for DCC 90
Eradication with treatment, %
for CIN1 [118-124] 97
for CIN2 [118,122,124,125] 93
for CIN3 [118,122,124,125] 93
for LCC [89] 92
for RCC [89] 55
for DCC [89] 17
for anogenital warts [41] 87.5/year
Persistence of HPV following eradication of CIN, % [127] 34
Persistence of HPV following eradication of cervical cancer, % [129] 47
Persistence of HPV following eradication of genital warts 34
Anogenital wart patients seeking physician care, % [71] 75
CIN = cervical intraepithelial neoplasia; DCC = distant cervical cancer; HPV = human papillomavirus; LCC = localized cervical cancer; RCC = 
regional cervical cancerBMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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shown to over-estimate the actual receipt and recency of
cervical cancer screening [96-101]. Two large U.S. studies
utilizing automated cervical cytology [47] and medical
claims [102] databases revealed annual proportions of
privately insured women receiving cervical cancer screen-
ing that were lower than those estimated from nationally
representative self-reported data for all women (privately
insured, publicly insured and uninsured) [104]. We there-
fore chose to estimate Pap screening utilization among
screened women using validated cytology data from the
Kaiser Permanente Northwest (KPNW) health plan [47]
and to estimate the proportion of women who are never
screened during their lifetimes from data sources that
include the uninsured and publicly insured. The decision
to separately specify the proportion of women never
screened was based on the observation that women with
little or no screening to account for a disproportionate
share (50–60%) of new cervical cancer cases [104,105].
The KPNW data were selected because they were derived
from a large sample of women (n = 150,052), provided a
detailed breakdown of annual Pap screening utilization
by age group, and distinguished between cervical and vag-
inal cytology and routine and non-routine Pap test-
ing[47]. The overall proportion of women receiving Pap
screening within KPNW each year was observed to be sim-
ilar to that in a large U.S. claims-based study of women
from across the U.S [102,106]. For modeling purposes,
two adjustments were made to annual age-specific routine
cervical cancer screening rates reported for KPNW. First,
the model assumes that women who have undergone
removal of the cervix through hysterectomy no longer
receive cervical cancer screening. The KPNW cervical can-
cer screening rates were based on cervical cytologic utiliza-
tion, and excluded vaginal cytologic screening among
women having undergone hysterectomy. However,
KPNW screening rates were reported across all women
including both those with and without a cervix. We there-
fore adjusted the rates to reflect screening frequencies
among women with a cervix using data reported in that
analysis on the proportion of women in each age group
estimated to have an intact cervix [47].
Second, KPNW screening rates reflect the experiences of
both screened (at least once in lifetime) and never
screened women. Because we wished to model the never
screened population separately, we elected to adjust the
rates in the screened population to reflect the removal of
never screened women from the denominator. Data on
the proportion of women who have never undergone cer-
vical cancer screening in the U.S. are only available from
studies featuring self-reported data. As discussed previ-
ously, for a variety of reasons [107], the proportion of
women who have never been screened in these studies is
likely to be under-reported. We chose to model 5% of
women as never receiving Pap screening, as this was con-
sistent with the upper end of estimates from the self-
reported literature [108,109] and yielded an overall frac-
tion of cervical cancer cases occurring among never
screened women (22%) roughly similar to that reported
in population-based studies [104].
Other data sources for cytology screening rates have been
used in forthcoming adaptations of our model to country
settings of the United Kingdom [110], Taiwan [111] and
Mexico [112].
Liquid-Based Cytology Sensitivity
As most cervical screening in the U.S. is now conducted
using liquid-based cytology (LBC) [113] we chose to
model test characteristics for that screening method. In
selecting studies for analysis of LBC sensitivity, we
excluded analyses which did not perform cervical biopsy
on at least a random sample of women with normal cytol-
ogy and colposcopy results. This criterion was established
because studies which do not biopsy these women will
tend to over-estimate the sensitivity of LBC when CIN or
cancer are present in women with normal cytology/col-
poscopy.
For assessing the sensitivity of LBC for CIN 1, the only
study observed to meet this criterion was conducted by
Bigras et al. in a non-high-risk Swiss population (n =
13,842) [117]. In the Bigras study, all women with an
abnormal Pap smear or high-risk HPV test were referred
for biopsy, with a random sample of 502 women with
normal Pap and HPV tests also undergoing biopsy. To cal-
culate LBC test characteristics, an extrapolation was made
from these two groups of patients to the full sample of
women. The sensitivity of LBC for CIN 1 lesions was esti-
mated to be 28%.
The sensitivity of LBC for CIN 2 and CIN 3 were also esti-
mated based on data from the Bigras study. Using data
reported in their paper, a sensitivity of 61% was computed
for CIN 2 and 55% for CIN 3, with an average sensitivity
for CIN 2/3 combined of 59% [115]. In a second study
that also selected women with normal cytology and HPV
results at random for biopsy, Kulasingam et al. estimated
a similar LBC sensitivity for CIN 3 or more severe disease
of 57% [12]. Based on these figures we elected to use an
LBC Pap test sensitivity for CIN 2/3 or more severe disease
of 59% in our base case analysis.
Liquid-Based Cytology Specificity
For assessing the specificity of LBC, we relaxed the criteria
for study eligibility to include studies in which all women
were referred for colposcopy, with a biopsy performed if
an abnormality was suspected. Studies conducted exclu-
sively or primarily among women with abnormal cytol-BMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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ogy results, or for which biopsy results for all grades of
CIN (1–3) were not reported were excluded. The decision
not to require that biopsy results be reported (or extrapo-
lated) for all women, including those with negative cytol-
ogy and HPV testing results, was based on the observation
from the Bigras analysis that test specificity (98% using
either criteria) is much less influenced by this requirement
than overall sensitivity for CIN 1–3 (31% vs. 45%) [114].
With a threshold for disease of biopsy-confirmed CIN 1, a
specificity of 98% was computed from the Bigras analysis
[114]. A specificity of 90% was computed from a second
study by Coste et al., conducted among French women
undergoing routine cervical cancer screening [115]. In the
Coste analysis, all women were referred for colposcopy,
with a biopsy performed if an abnormality was suspected
[115,116]. Based on these analyses, we estimated an aver-
age specificity for LBC with a disease threshold of CIN 1
of 94%.
Colposcopy Sensitivity
A meta-analysis by Mitchell et al. examined studies in
which women with an abnormal Pap smear underwent
both colposcopy and colposcopically directed biopsy,
with results tabulated by grade of CIN and cancer [117].
Nine studies met the review eligibility criteria, with a
mean sensitivity for colposcopy to detect histologic
abnormalities (including CIN 1–3 and cancer) of 96%.
Colposcopy Specificity
The meta-analysis by Mitchell et al. also reported a mean
specificity for colposcopy of 48%, and this figure was used
in the model [117].
Symptom Development Among Cervical Cancer Patients
It was assumed that women not diagnosed with asympto-
matic cervical cancer through screening would be diag-
nosed if symptoms developed. The literature review did
not identify any studies describing stage-specific symptom
development in a representative cross-section of patients
with cervical cancer. A difficulty in interpreting existing
case series is that it is not possible to determine the true
number of women within the population who harbor
asymptomatic cervical cancer. In the absence of such data,
we reviewed assumptions used in prior cost-effectiveness
analyses [7,9,21,22] and chose an annual probability of
initially developing symptoms for LCC of 4%, RCC of
18%, and DCC of 90%.
Eradication of CIN following treatment
For estimating the rate of eradication of CIN following
treatment, we selected studies evaluating the performance
of the commonly used LEEP procedure, subject to the fol-
lowing criteria: 1) Stratified reporting by CIN grade of the
number of subjects with confirmed pre-treatment histol-
ogy of CIN 1, 2 or 3; 2) Post-treatment follow-up of all
women within 12 months with colposcopy and/or
biopsy; 3) Definition of recurrent or residual disease as
CIN 1 or more severe histology; 4) Stratified reporting of
the number of subjects with recurrent/residual disease
according to the grade of pre-treatment histology.
Seven studies evaluating the treatment of CIN 1 met the
review eligibility criteria, comprising 417 cases [118-124].
A total of 14 cases of residual/recurrent CIN were reported
in these studies, for a treatment eradication rate of 97%.
For CIN 2, seven eligible studies (n = 403, 30 cases of
residual/recurrent CIN) [118-124] yielded a treatment
eradication rate of 93%, and for CIN 3, eight eligible stud-
ies (n = 1,565, 109 cases of residual/recurrent CIN) [118-
122,124-126] a rate of 93%. Limitations of the pooled
analysis included that data were insufficient to evaluate
treatment efficacy for HPV 16/18 or 6/11 lesions specifi-
cally and, with the exception of one small study [118]
women with negative colposcopies during follow-up were
not biopsied.
Eradication of cervical cancer following treatment
For cervical cancer, it was assumed that women surviving
for more than 5 years following diagnosis were cured of
disease [89]. We therefore utilized 5-year relative survival
rates by stage from the SEER program to estimate the pro-
portion of women whose cancers were successfully eradi-
cated with treatment [90]. For the period 1995–2001, the
5-year relative survival rate for localized cervical cancer in
the SEER program was 92%, for regional cancer 55%, and
for distant cancer 17%. An age and stage-specific mortality
rate was modeled for women not cured of their cancers, as
described in the previous section on cervical cancer mor-
tality.
Eradication of anogenital warts following treatment
For anogenital warts, current treatments often require
multiple applications and often fail, requiring second and
third-line therapies [87]. Rather than modeling treatment
algorithms explicitly, a global 12-month clearance rate
with treatment of 87.5% was assumed, based on the
Winer study as previously described [41].
Persistence of cervical HPV infection following eradication of CIN
Women whose CIN is successfully removed and who do
not develop recurrent CIN may still harbor HPV infection
transmissible to others. To inform this model parameter,
we searched for studies in which: 1) HPV testing was
reported specifically for HPV types 16/18 or 6/11; 2) HPV
DNA testing was performed on pre-treatment biopsies or
treatment specimens of confirmed CIN histology; 3) Fol-
low-up for all women and HPV testing occurred within 6
months post-treatment; 4) Colposcopy was performed on
all women during follow-up to confirm the eradication of
CIN lesions; 5) Persistent CIN disease during follow-upBMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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(to be excluded) was confirmed by histology. One previ-
ous study was identified which met these criteria. Cruick-
shank et al. studied women who were treated for CIN 3 via
LEEP and laser ablation, had negative Pap smears and col-
poscopic assessments at 6 months, and remained free of
disease thereafter for a minimum of 5 years [127]. HPV
testing and typing was conducted using tissue obtained
from the diagnostic biopsy and cytologic material from
the 6 month follow-up smear. Among women with HPV
16/18 infection detected in the diagnostic biopsy (n = 35),
12 (34%) had detectable HPV 16/18 infection at their 6
month post-treatment smear. We therefore assumed that
this percentage of women successfully treated for CIN
maintained cervical HPV infection following therapy as
other studies with similarly rigorous HPV typing and fol-
low-up regimens were not identified. It should be noted
that the clearance of HPV infection in the cervix, coincid-
ing with treatment for CIN, may have little influence with
respect to the clearance of HPV infection co-existing at
other anogenital sites, although in the model HPV infec-
tions were not site-specific [15]. Paraskevaidas et al., have
also reviewed the persistence of HPV infection more gen-
erally (regardless of HPV infection type), following CIN
eradication [128].
Persistence of HPV infection following eradication of cervical cancer
One study was identified through the literature review
evaluating the PCR-based type-specific persistence of HPV
infection following treatment for cervical cancer [129].
Fen et al. performed HPV typing of cervical swabs prior to
hysterectomy among women with Stage I and II cervical
cancers and compared results to swab samples taken from
the residual endocervix or vaginal mucosa 6–24 months
following treatment. Among women with HPV 16/18
infection prior to treatment (n = 30), 46.7% had persist-
ent HPV infection with the same type following hysterec-
tomy [129]. Limitations of the study with respect to the
present review include that results were not stratified by
recurrence status and the time interval to post-treatment
HPV testing was at least several months. Other studies
overcoming these limitations were not found.
Persistence of HPV infection following eradication of genital warts
The literature review identified two studies comparing the
type-specific prevalence of HPV 6/11 infection prior to
and following successful eradication of genital warts. The
first, by Arany et al., evaluated 6 patients successfully
treated via interferon therapy for HPV 6/11 positive geni-
tal warts and found 100% clearance of HPV 6/11 infection
within normal skin at the wart site at 6–12 weeks follow-
up [130] The second, by Syed et al., also reported com-
plete elimination of HPV 6/11 infection at 12 months fol-
lowing eradication of warts with imiquimod cream,
however, the number of patients testing positive for HPV
6/11 infection at baseline, and negative at follow-up, were
not specified [131]. Limitations of both studies for pur-
poses of the present review included a lack of information
as to whether HPV infection was present on follow-up
across a sampling of anogenital sites. Because the sample
size in the first study was quite small, and the time to fol-
low-up PCR testing in the second study rather long, we
assumed a similar rate of persistence of HPV infection fol-
lowing eradication of anogenital warts as estimated for
CIN (34%) in the model.
Anogenital wart patients seeking physician care
Not all patients who harbor anogenital warts will be
aware of their presence or seek physician care [132,133].
In the Winer study, used to estimate the rate of anogenital
warts following incident HPV 6/11 infection, all women
underwent Pap screening, colposcopy and HPV testing at
4 month intervals [41]. As a result of the frequent clinical
examinations, it is possible that some women who would
have otherwise remained undetected were diagnosed and
treated for their warts. Although precise data are unavail-
able, Chesson et al. estimated that approximately 25% of
patients with anogenital warts will not seek or require
physician care and we utilized this figure [72].
Discussion
Natural history models of HPV disease are increasingly
being used to inform policy making for existing and
emerging technologies [7-11,13-15,21,24,44]. This paper
has critically reviewed the evidence base for modeling the
natural history, clinical diagnosis and treatment of cervi-
cal HPV disease and anogenital warts, available at the time
of development of our multi-HPV type model [14]. Prior
reviews and meta-analyses of the natural history of HPV
disease have typically pooled data from studies of varying
quality and design (e.g., not distinguishing between cervi-
cal cytology and histology) for the purposes of analysis
[27-30]. A unique feature of this review has been the uti-
lization of stricter study eligibility criteria in an attempt to
select more homogeneous data sources perceived to be of
the highest quality presently available. Given that the
quantity of eligible studies was small for a number of
model parameters, in conducting policy evaluations,
modelers should be prepared to conduct sensitivity anal-
yses varying those parameters found to be most influen-
tial to the study outcomes of interest [7-11,13-
15,21,24,44]. We should also note that the relatively
small number of studies available to inform the modeling
parameters was an impetus for us to conduct additional
studies to better characterize these inputs, reflecting sev-
eral of the references discussed in this review
[42,43,47,73].
Given the breadth and complexity of HPV disease mode-
ling, we have not comprehensively reviewed data to
inform all possible model structures and permutations, orBMC Infectious Diseases 2009, 9:119 http://www.biomedcentral.com/1471-2334/9/119
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every potential limitation of existing studies to inform
such models. Furthermore, although we attempted to be
thorough in our review, it is also possible that our data-
base and non-database search strategies may have missed
some publications of relevance as we did not search all
publicly available scientific literature databases (e.g.,
EMBASE, PsycLIT). However, the present review has
attempted to highlight available data sources and associ-
ated major strengths and limitations for informing
parameters common to many existing models.
Conclusion
Knowledge of the natural history of HPV disease has been
considerably enhanced over the past two decades,
through the publication of an increasing number of rele-
vant studies. However, considerable opportunity remains
for advancing our understanding of HPV natural history
and the quality of associated models. For instance, more
studies examining the type-specific progression and
regression of HPV disease are needed, both for more accu-
rate modeling of disease natural history and to inform
policymaking for technologies such as vaccines that target
specific HPV types [7,14,15]. Also, additional studies
stratifying progression and regression rates for CIN by age
would be helpful in resolving the issue of whether these
rates are constant across age or age-dependent. Finally,
studies exploring the potential duration of acquired
immunity following HPV infection are needed.
For many disease areas, modeling is an iterative process.
As one's understanding of disease natural history and clin-
ical management are advanced, existing models can be
adapted to incorporate new evidence. Comprehensive lit-
erature reviews for HPV disease and other health condi-
tions can play an important role in assisting modelers and
policymakers in critically evaluating the current evidence
base and identifying areas for future study.
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